EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Clinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations

Keyu Chen iD, Yufen Xu, Binbin Song, Yuyang Gu, Xiaofang Xu, Jun Cao, Meiyu Fang

Molecular Genetics & Genomic Medicine · 2026

DOI: 10.1002/mgg3.70177 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Genetics & Genomic Medicine, 2026. Verfasst von Keyu Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Hospital of Jiaxing & The Affiliated Hospital of Jiaxing University, Jiaxing, China. Hauptthemen laut MEDLINE: Li-Fraumeni Syndrome, Tumor Suppressor Protein p53, Germ-Line Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Li‐Fraumeni syndrome is a rare autosomal dominant disorder caused by a pathogenic mutation of the tumor suppressor gene TP53 . This disease starts at an early age and has been shown to be associated with multiple tumors. The study aims to discuss the clinical and genetic characteristics of Li‐Fraumeni syndrome (LFS) and to provide therapeutic experience of LFS. Materials and Methods We conducted a retrospective analysis of the clinicopathologic features, family history, treatment and follow‐up in five LFS patients with germline TP53 (NCBI Gene: 7157 , HGNC: 11998 , OMIM: 191170 ) pathogenic/likely pathogenic (P/LP) variants. This research had been approved by the ethics committee and implemented.

Results

Our study involved five LFS patients with germline TP53 P/LP variants, including thyroid cancer, ovarian melanoma, colon cancer, fibrosarcoma, and lung cancer. Among this group of patients, the age at which tumors first appeared was between 24 and 53 years old. Three patients had a family history of tumors, and the other two were probands in the family. Traditional chemotherapy has limited effectiveness in clinical practice and may increase the risk of tumor development. However, immune checkpoint inhibitors (ICIs) have shown unexpected efficacy in patients with high programmed cell death ligand‐1 (PD‐L1) expression. Next‐generation sequencing (NGS) and PD‐L1 detection may provide more potential targets for LFS patients to achieve better therapeutic outcomes. In addition, we have added a new TP53 frameshift mutation spectrum, namely c.642_643delTA (p.H214Qfs*7), which belongs to the pathogenic variant. This mutant has not been described in the existing literature.

Conclusion

Patients with LFS may be potential beneficiaries of immune checkpoint inhibitors and targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Li-Fraumeni SyndromeTumor Suppressor Protein p53Germ-Line MutationHumansFemaleAdultMiddle AgedMaleYoung AdultRetrospective StudiesPedigreeImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Li‐Fraumeni syndromeTP53 pathogenic/likely pathogenic variantsgermline mutationshereditary diseaseimmune checkpoint inhibitors

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • The First Hospital of Jiaxing & The Affiliated Hospital of Jiaxing University, Jiaxing, China.
  • Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Department of Head and Neck and Rare Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science…

ORCID-Profile: Keyu Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, K., Xu, Y., Song, B., Gu, Y., Xu, X., Cao, J., & Fang, M. (2026). Clinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70177

Vancouver

Chen K, Xu Y, Song B, Gu Y, Xu X, Cao J, et al. Clinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations. Molecular Genetics & Genomic Medicine. 2026. doi:10.1002/mgg3.70177

BibTeX
@article{Chen2026,
  author = {Chen, Keyu and Xu, Yufen and Song, Binbin and Gu, Yuyang and Xu, Xiaofang and Cao, Jun and Fang, Meiyu},
  title = {Clinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations},
  journal = {Molecular Genetics & Genomic Medicine},
  year = {2026},
  doi = {10.1002/mgg3.70177}
}
Kostenlos starten →